¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Host Cell Factor C1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • embryonic stem cell
    ¹è¾ÆÁٱ⼼Æ÷
  • endothelial cell
    ³»ÇǼ¼Æ÷
  • enterochromaffine cell
    âÀÚÅ©·Òģȭ¼¼Æ÷, ÀåÅ©·Òģȭ¼¼Æ÷
  • enteropathy-type T-cell lymphoma
    À庴ÁõÇüT¼¼Æ÷¸²ÇÁÁ¾
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • epithelioid cell nevus
    »óÇǸð¾ç¼¼Æ÷¸ð¹Ý
  • erythroid cell
    ÀûÇ÷±¸
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • ethmoidal air cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal cell
    ¹úÁý, »ç°ñºÀ¼Ò
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • dendritic cell
    °¡Áö¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diploid cell
    µÎ¹è¼öü¼¼Æ÷
  • duct cell carcinoma
    °ü¼¼Æ÷¾ÏÁ¾
  • dust cell
    ¸ÕÁö¼¼Æ÷
  • effector cell
    ÀÛµ¿¼¼Æ÷
  • egg cell
    ³­¼¼Æ÷, ¾Ë¼¼Æ÷
  • endothelial cell
    ³»ÇǼ¼Æ÷
  • enterochromaffine cell
    âÀÚģũ·Ò¼¼Æ÷, âÀÚÅ©·Òģȭ¼¼Æ÷
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • erythroid cell
    (¢¡red blood cell) ÀûÇ÷±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • ghost cell glaucoma
    ºó¼¼Æ÷³ì³»Àå, À¯·É¼¼Æ÷³ì³»Àå
  • giant cell aortitis
    °Å´ë¼¼Æ÷¼º ´ëµ¿¸Æ¿°
  • giant cell arteritis
    °Å¼¼Æ÷(¼º) µ¿¸Æ¿°
  • giant cell arteritis=temporal arteritis
    °Å¼¼Æ÷µ¿¸Æ¿°
  • giant cell carcinoma
    °Å¼¼Æ÷¾ÏÁ¾
  • giant cell epulis
    °Å¼¼Æ÷Ä¡ÀºÁ¾.
  • giant cell fibroblastoma
    °Å´ë¼¼Æ÷ ¼¶À¯¸ð¼¼Æ÷Á¾
  • giant cell glioma
    °Å¼¼Æ÷±³Á¾.
  • giant cell granuloma
    °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • giant cell granuloma,reparative
    ¼öº¹¼º °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • giant cell histiocytoma
    °Å´ë¼¼Æ÷ Á¶Á÷±¸Á¾
  • giant cell leukemia
    °Å¼¼Æ÷¹éÇ÷º´.
  • giant cell myeloma
    °Å¼¼Æ÷°ñ¼öÁ¾.
  • giant cell myocarditis
    °Å´ë¼¼Æ÷¼º ½É±Ù¿°(¡­ãýÐÉæú)
  • giant cell pneumonia
    °Å¼¼Æ÷Æó·Å.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • lymphocytosis promoting factor
    ¸²ÇÁ±¸Áõ°¡Áõ ÃËÁøÀÎÀÚ
  • lymphocytosis promoting factor
    ¸²ÇÁ±¸Áõ°¡Áõ ÃËÁø ÀÎÀÚ
  • lymphocytosis stimulating factor =LSF
    ¸²ÇÁ±¸Áõ°¡ÀÚ±ØÀÎÀÚ(¡­Ï¹ñòÊ¥ô§Ð½ ì×í­).
  • lymphocytosis-promoting factor
    ¸²ÇÁ±¸Áõ´ÙÁõÃËÁøÀÎÀÚ
  • lytic factor
    ¿ëÇØÀÎÀÚ(éÁú°ì×í­).
  • macrophage activating factor (MAF)
    ´ë½Ä¼¼Æ÷ Ȱ¼ºÀÎÀÚ
  • macrophage aggregating factor
    ´ë½Ä¼¼Æ÷ °áÁýÀÎÀÚ
  • macrophage arming factor
    ´ë½Ä¼¼Æ÷ ¹«ÀåÀÎÀÚ
  • macrophage chemotactic and activating factor
    ´ë½Ä¼¼Æ÷ ÁÖÈ­ ¹× Ȱ¼º ÀÎÀÚ
  • macrophage chemotactic factor (MCF)
    ´ë½Ä¼¼Æ÷ È­ÇÐÁÖ¼ºÀÎÀÚ
  • macrophage colony-stimulating factor(M-CSF)
    ´ë½Ä¼¼Æ÷ Áý¶ô ÀÚ±ØÀÎÀÚ
  • macrophage migration inhibition factor(mif)
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ (MIF) (¡­ë´ñËîÁò­ì×í­)
  • macrophage migration inhibitory factor
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ.
  • macrophage,macrophage derived growth factor
    ´ë½Ä¼¼Æ÷±â¿ø ¼ºÀåÀÎÀÚ(¡­ÑÃê¹ à÷íþì×í­)
  • maturation factor
    (ÀûÇ÷±¸)¼º¼÷ÀÎÀÚ(ËøÌ´Ë´ËÛ ËàËöËö).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • thymidine factor
    ŸÀ̵̹ò ÀÎÀÚ (ì×í­)
  • thyrotropic hormone releasing factor
    °©»ó¼±ÀÚ±Ø(Ë£ßÒàÍí©Ð½) È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í­)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • tissue factor
    Á¶Á÷ÀÎÀÚ (ðÚòÄì×í­)
  • transfer factor
    "ÀüÀÌ(ï®ì¹) ÀÎÀÚ(ì×í­), Àü´ÞÀÎÀÚ(îîÓ¹ì×í­)"
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • translocation factor
    ÀüÀ§ ÀÎÀÚ(ï®êÈì×í­)
  • TR factor
    TR ÀÎÀÚ(ì×í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • two-factor cross
    ÀÌÀÎÀÚ ±³Â÷(ì£ì×í­Îßó©)
  • van't Hoff factor
    ¹ÝÆ® È£ÇÁ ÀÎÀÚ(ì×í­)
  • von Willebrand factor
    Æù ºô·¹ºê¶õÆ® ÀÎÀÚ (ì×í­)
  • Willebrand factor
    ºô·¹ºê¶õÆ® ÀÎÀÚ (ì×í­)
  • xathine oxidase factor
    À鯾 ¿Á½Ãµ¥À̽º ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
LF labile factor; lactoferrin; laryngofissure; Lassa fever; latex fixation; left foot; left forearm; le...
LRF latex and resorcinol formaldehyde; liver residue factor; luteinizing hormone-releasing factor
LRSF lactating rat serum factor; liver regenerating serum factor
LTF lactotransferrin; lipotropic factor; lymphocyte-transforming factor
MAF macrophage activation factor; macrophage agglutinating factor; maximum atrial fragmentation; minimum...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
AECA Anti-endothelial cell antibodies
RBC Anti-red blood cell
SRBC Anti-sheep red blood cell
ADCC Antibody Dependent Cell Cytotoxicity
ADCC Antibody Dependent Cell-Mediated Cytotoxicity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • eosinophilic cell
    È£»ê±¸
  • epidermoid type cell
    À¯Ç¥ÇÇ ¼¼Æ÷
  • epithelioid cell
    »óÇÇ¾ç ¼¼Æ÷, À¯»óÇÇ ¼¼Æ÷
    °áÇÙ µîÀÇ À°¾Æ¼º ¿°Áõ Áúȯ¿¡ À־ À°¾Æ ¼Ó¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ´Â Á¶Á÷±¸ÀÇ È£Äª.
  • ethmoid cell
    »ç°ñ ¹úÁý, »ç°ñ ºÀ¼Ò
  • eukaryotic cell
    ÁøÇÙ ¼¼Æ÷
  • excretory cell
    ¹è¼³ ¼¼Æ÷
  • fat cell
    Áö¹æ ¼¼Æ÷
  • fetal liver cell
    ÅÂ¾Æ °£ ¼¼Æ÷
    ÅÂ¾Æ °£ ¼¼Æ÷, Á¶Ç÷ stem ¼¼Æ÷°¡ µé¾î ÀÖ°í, µû¶ó¼­ °¢Á¾ ¸é¿ª ¼¼Æ÷ÀÇ Àü±¸ ¼¼Æ÷¸¦ Æ÷ÇÔÇÑ´Ù. ÃÖ±Ù ¸é¿ªºÎÀüÀÇ Áúȯ, ¿¹¸¦ µé¸é ÁßÁñ º¹ÇÕ ¸é¿ª ºÎÀüÁõ¿¡¼­´Â Á¶Á÷ ÀûÇÕ °ñ¼ö¸¦ ¾òÁö ¸øÇÏ´Â °æ¿ì, 8ÁÖ ÀÌÀüÀÇ ÅÂ¾Æ °£¼¼Æ÷ÀÇ À̽ÄÀÌ ÀÌ·ç¾îÁ® Àå±â°£ÀÇ »ýÁ¸ ¿¹¸¦ º¼ ¼ö ÀÖ´Ù.
  • fibroma-theca cell tumor
    ¼¶À¯Á¾-³­Æ÷¸· ¼¼Æ÷Á¾
    ¼¶À¯¾Æ¼¼Æ÷³ª ³­Æ÷¸· ¼¼Æ÷·Î ±¸¼ºµÈ´Ù. ±¸¼º ¼¼Æ÷°¡ ´ëºÎºÐ ³­Æ÷¸· ¼¼Æ÷ÀÎ ÀÌ Á¾¾çÀº È£¸£¸óÀ» »ý»êÇÒ ¼ö ÀÕ´Ù. ±×·¯³ª ¼ø¼öÇÑ ³­Æ÷¸· ¼¼Æ÷Á¾Àº µå¹°°í ´ëºÎºÐ Á¾¾çÀº ÁÖ·Î ¼¶À¯¸ð¼¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç È£¸£¸óÀ» »ý»êÇÏÁö ¾Ê´Â´Ù. 90%¿¡¼­ ÇÑÂÊ ³­¼Ò¿¡¼­¸¸ ¹ß»ýÇÑ´Ù. Á¾¾çÀº ȸ¹é»öÀÌ¸ç °íÇüÀÌ°í ±¸ÇüÀÌ¸ç ´Ü´ÜÇÏ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¼¶À¯¸ð¼¼Æ÷¿Í ÄݶóÁ¨ °áü Á¶Á÷À¸·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç ³­Æ÷¸· ¼¼Æ÷°¡ È¥ÀçÇÒ ¼ö ÀÖ´Ù. ȯÀÚ´Â °ñ¹ÝÅë°ú °ñ¹Ý Á¾±« µîÀÇ ºñƯÀÌÀû Áõ»óÀ» È£¼ÒÇϰųª º¹¼ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ³­Æ÷¸· ¼¼Æ÷Á¾Àº ¾Ç¼ºÀÌ ¾ø´Ù.
  • fibrosing basal cell carcinoma
    ¼¶À¯¼º ±âÀú ¼¼Æ÷ ¾Ï
  • Finkeldey cell
    ÇÉÄ̵¥ÀÌ ¼¼Æ÷
    ¸¶Áø ȯÀÚÀÇ ÀÓÆÄ Á¶Á÷¿¡¼­ º¼ ¼ö ÀÖ´Â °Å´ë ¼¼Æ÷.
  • foam cell
    Æ÷¸» ¼¼Æ÷
  • follicular cell
    ¼ÒÆ÷ ¼¼Æ÷, ³­Æ÷ ¼¼Æ÷
  • foreign body giant cell
    À̹° °Å´ë ¼¼Æ÷, À̹° °Å¼¼Æ÷
  • hair cell
    ¸ð ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
extinction factor <microscopy> In a polarizing or Differential Interference Contrast microscope, the ratio of the amount of light that is transmitted with the axes of the polars parallel over the amount transmitted with their axes crossed.
Unless the lenses are rectified, the extinction factor drops exponentially as the numerical aperture is increased.
Acronym: EF
(26 Mar 1998)
extrinsic factor Dietary vitamin B12.
(05 Mar 2000)
extrinsic factor deficiency <disease> An inherited disorder that causes abnormal blood clotting due to the congenital absence of one of the 20 different plasma proteins involved in the coagulation process.
Symptoms include bleeding of the gums, nosebleeds, easy bruising, bleeding in muscles or joints and excessive menstrual bleeding.
Treatment includes the administration of plasma concentrates of factor VII (extrinsic factor).
(27 Sep 1997)
factor <pharmacology> Any of several substances or activities that are necessary to produce a result, for example a coagulation factor.
Often, use of the term factor indicates that the chemical nature of the substance or its mechanism of action is unknown, as in endocrinology, where factors are renamed as hormones when their chemical nature is determined.
(18 Nov 1997)
factor 3 Operational name given to an incompletely characterised selenium-containing natural product which, in minute amounts, prevents liver damage in rats due to deficiency of vitamin E, factor III in the vitamin B12 series, 5-hydroxybenzimidazole, analogue of the usual B12 nucleotide components.
(05 Mar 2000)
factor A A component of the properdin system; a hydrazine-sensitive b1-globulin (mw about 180,000), now known to be C3 (third component of complement).
(05 Mar 2000)
factor analysis, statistical A set of statistical methods for analyzing the correlations among several variables in order to estimate the number of fundamental dimensions that underlie the observed data and to describe and measure those dimensions. It is used frequently in the development of scoring systems for rating scales and questionnaires.
(12 Dec 1998)
factor B <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase.
Registry number: EC 3.4.21.47
(12 Dec 1998)
factor D <enzyme> A serum protein which during the alternate pathway of complement activation converts the inactive properdin factor b to c3 convertase.
Registry number: EC 3.4.21.46
(12 Dec 1998)
factor E A serum protein (mw 160,000) required for activation of C3 (third component of complement) by cobra venom factor.
See: properdin system.
(05 Mar 2000)
factor Gm A factor that determines certain of the allotypes of human immunoglobulins; found only on the g chains of IgG (gamma-globulin).
(05 Mar 2000)
factor H Former designation for biotin, vitamin B12 analogue or precursor, a glycoprotein that regulates the activity of complement factor C3b; a deficiency results in the lack of inhibition of the alternative haemolytic pathway leading to continuous activation and consumption of factor C3 (haemolytic uraemic syndrome).
(05 Mar 2000)
factor I <haematology> A protein which is synthesised by the liver.
Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting.
A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen.
Synonym: fibrinogen.
(15 Nov 1997)
factor II <haematology> A protein which is synthesised by the liver.
Fibrinogen is converted to fibrin, in the formation of a blood clot, via the enzymatic action of thrombin. A fibrinogen assay measures the concentration of fibrinogen in the blood and may be used to evaluate abnormal blood clotting.
A lack of fibrinogen may be congenital or acquired. A condition known as DIC results in the excessive utilisation and depletion of fibrinogen.
Synonym: thrombin.
(15 Nov 1997)
factor IIa <enzyme> Protease (34 kD) generated in blood clotting that acts on fibrinogen to produce fibrin. Consists of two chains, A and B, linked by a disulphide bond. B chain has sequence homology with pancreatic serine proteases: cleaves at Arg Gly.
Thrombin is produced from prothrombin by the action either of the extrinsic system (tissue factor + phospholipid) or, more importantly, the intrinsic system (contact of blood with a foreign surface or connective tissue). Both extrinsic and intrinsic systems activate plasma factor X to form factor Xa which then, in conjunction with phospholipid (tissue derived or platelet factor 3) and factor V, catalyses the conversion.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á